Exec Chat: As Reimbursement Questions Get Answers, iRhythm Looks To The Future
Executive Summary
Medtech Insight caught up again with iRhythm CEO Quentin Blackford about his vision for the company as it plans for the next five to ten years of expansion in the remote cardiac monitoring and arrhythmia diagnostics market.
You may also be interested in...
Exec Chat: New iRhythm CEO Foresees Enormous Opportunity In AI For Arrhythmia Detection
Quentin Blackford, who recently became iRhythm’s CEO after serving as Dexcom’s chief operating officer, talked to Medtech Insight about the challenges and opportunities in the emerging remote cardiac monitoring market.
Updated: iRhythm Continues To Grow Despite Reimbursement, Hospital-Staffing Challenges
Despite intense lobbying from industry and physician groups, CMS chose not to install national pricing for long-term remote cardiac monitoring in its final 2022 Medicare Physician Fee Schedule Final Rule.
Verily And iRhythm Agree To Collaborate On Atrial Fibrillation
Verily Life Sciences and iRhythm Technologies have agreed to co-develop technology for screening, diagnosing and managing patients with atrial fibrillation, combining iRhythm’s artificial intelligence system for diagnosing arrhythmias with Verily’s health data analytics technology.